Ligand Pharmaceuticals (LGND) Income towards Parent Company (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 15 years of Income towards Parent Company data on file, last reported at -$13.3 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 68.56% year-over-year to -$13.3 million; the trailing twelve-month figure through Mar 2026 stood at $153.6 million (up 308.81% YoY), and the FY2025 full-year result was $124.5 million, up 3186.63% from the prior year.
• Income towards Parent Company fell to -$13.3 million in Q1 2026, from $44.8 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $117.3 million in Q3 2025 to a low of -$42.5 million in Q1 2025.
• A 5-year average of $4.6 million and a median of -$3.0 million in 2022 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company sank 136.03% in 2022 and surged 244.06% in 2025, its largest moves.
• Tracing LGND's Income towards Parent Company over 5 years: stood at -$3.0 million in 2022, then surged by 43.58% to -$1.7 million in 2023, then slumped by 1767.15% to -$31.1 million in 2024, then surged by 244.06% to $44.8 million in 2025, then plunged by 129.8% to -$13.3 million in 2026.
• Business Quant data shows LGND's Income towards Parent Company at -$13.3 million in Q1 2026, $44.8 million in Q4 2025, and $117.3 million in Q3 2025.